IRLA Stock Forecast: IRulya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$40
−0.15% on the day

The 8 Wall Street analysts covering IRulya Therapeutics, Inc. hold a median 12-month price target of $71 — +78.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$432.4M
Ticker Nerd rank
33/ 100
Median analyst target
$71
Analysts covering
8
Revenue$0.0
Operating income−$22.1M
Net income−$75.5M
Free cash flow−$18.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.2%
1M
−1.0%
YTD
−94.0%
1Y
−90.2%
From 52W high
−95.5%
From 52W low
+149.3%
$16
$880
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IRulya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
33/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Value
59
Issuance
55
Growth
54
Revisions
27
Volatility
24
Quality
21
Momentum
14

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IRLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$200$400$600$800Jan 26Apr 26Jul 26Oct 26IRLAHigh $98Median $71Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$65
Low
$71
Median
$98
High

The green dot is the last close — the median target sits +78.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2026Cantor FitzgeraldReiteratesOverweight$70
16 Nov 2026CitizensMaintainsMarket Outperform$77 → $86
9 Oct 2026Raymond JamesInitiatesOutperform$72
24 Sept 2026Rodman & RenshawInitiatesBuy$70
22 Sept 2026CitizensUpgradeMarket Outperform$77
18 Aug 2026Cantor FitzgeraldReiteratesOverweight$70
29 July 2026OppenheimerInitiatesOutperform$82
24 June 2026Leerink PartnersInitiatesOutperform$4.00
23 June 2026Cantor FitzgeraldInitiatesOverweight$4.00
30 Jan 2026CitizensDowngradeMarket Perform—
30 Jan 2026D. Boral CapitalDowngradeHold—
29 Jan 2026D. Boral CapitalMaintainsBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
26 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
12 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
5 Aug 2025JMP SecuritiesInitiatesMarket Outperform—
17 July 2025D. Boral CapitalMaintainsBuy—
13 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRLA.

Market Radar

This page is one stock. Monday covers all of them.

IRLA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IRLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IRulya Therapeutics, Inc. returned −90.2% against +6.9% for the S&P 500, dividends included.

IRLA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26IRLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−37.2%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IRulya Therapeutics, Inc. has a market value of $432.4M and an enterprise value of $465.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$92.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$47.0M.

  • Shares outstanding: 10.8M.

  • IRulya Therapeutics, Inc. employs 38 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

IRLA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IRLAIRulya Therapeutics, Inc.$432.4M33
INDPIndaptus Therapeutics, Inc.$433.1M25
OCSOculis Holding AG$435.8M30
CAPRCapricor Therapeutics, Inc.$436.5M13
CTMXCytomX Therapeutics, Inc.$438.8M46
ASMBAssembly Biosciences, Inc.$439.7M79
ARVNArvinas, Inc.$423.0M74

Take a look at IRLA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IRulya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IRLA

What is the IRLA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering IRulya Therapeutics, Inc. have a median 12-month price target of $71, with estimates ranging from $65 to $98. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRLA stock a buy right now?

Of the 8 analysts covering IRulya Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRulya Therapeutics, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRLA?

As at 21 Nov 2026, IRulya Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will IRLA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +78.0% from the last close, and Ticker Nerd's factor model ranks IRulya Therapeutics, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRLA stock forecast for 2030?

No analyst covering IRulya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $98 over the next 12 months.

How has IRLA stock performed over the past year?

IRulya Therapeutics, Inc. returned -90.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IRulya Therapeutics, Inc. do?

IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions. Its primary program, LAM-001, is an investigational inhaled dry-powder formulation of rapamycin designed to address pulmonary diseases associated with dysregulated mammalian target of rapamycin activity.

Company

About IRulya Therapeutics, Inc.

IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions. Its primary program, LAM-001, is an investigational inhaled dry-powder formulation of rapamycin designed to address pulmonary diseases associated with dysregulated mammalian target of rapamycin activity. Current development areas include pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome following lung transplantation, and sarcoidosis-associated pulmonary hypertension. The company’s work combines drug formulation, inhalation delivery, and targeted clinical development to support potential treatments for complex respiratory disorders. IRulya Therapeutics Inc. operates within the biotechnology and specialty pharmaceuticals markets, serving an area where conventional treatment options may not adequately address underlying disease mechanisms. Its business is centered on advancing proprietary therapeutic candidates through clinical research and regulatory development, positioning the company as a focused participant in the pulmonary medicine sector.

CEO Dr. Brigette Roberts M.D. · 38 employees · United States · https://irulya.com